Vanda Pharmaceuticals stock's explosive rally may be more hype than substance

Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA's approval for its treatment of schizophrenia and bipolar I disorder. The BYSANTI (milsaperidone) announcement is a welcome reprieve for VNDA that's been under pressure this year as investors weighed “disappointing” Q4 earnings against a backdrop of clinical uncertainty.

Invezz • Feb 23, 2026

Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment

Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading higher during the premarket session on Monday following the announcement of FDA approval for Bysanti (milsaperidone), a new treatment for bipolar I disorder and schizophrenia.

Benzinga • Feb 23, 2026

Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy

Vanda Pharmaceuticals Inc. has received FDA approval for BYSANTI, a new atypical antipsychotic targeting bipolar I disorder and schizophrenia. VNDA now markets five products, but BYSANTI's differentiation from Fanapt is questioned due to similar active molecules and looming patent expiry. 2025 saw Fanapt sales up 24%, but VNDA posted a $(220.5m) net loss and expects higher cash burn in 2026, raising funding concerns.

Seeking Alpha • Feb 23, 2026

US FDA approves Vanda's psychiatric drug

The U.S. Food and Drug Administration has approved Vanda Pharmaceutical's drug for the treatment of two serious mental health conditions, the company said on Friday.

Reuters • Feb 20, 2026

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. BYSANTI™ is a new chemical entity (NCE) that belongs in the class of atypical antipsychotics.

PRNewsWire • Feb 20, 2026

Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week

Vanda Pharmaceuticals reported weak FY25 results, with a GAAP EPS miss and heavy losses, despite 9% revenue growth driven by Fanapt. VNDA's valuation is deeply discounted, trading at 1.4x forward sales and 0.5x EV/sales, reflecting high regulatory and execution risk. Upcoming catalysts include the Nereus launch and Bysanti's PDUFA decision; approval could diversify revenues but is far from guaranteed.

Seeking Alpha • Feb 19, 2026

Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript

Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 14, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Feb 12, 2026

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024 Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024 NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motion Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026 WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025. "2025 showed strong momentum at Vanda, led by Fanapt, with net product sales up 24% to $117.3 million, driven by a 28% rise in total prescriptions and 149% surge in new-to-brand prescriptions - reflecting accelerating growth in schizophrenia and bipolar I disorder.

PRNewsWire • Feb 11, 2026

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $2.18. This compares to a loss of $0.08 per share a year ago.

Zacks Investment Research • Feb 11, 2026